Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer
The purpose of this study is to determine if the addition of ZD1839 Iressa™ to standard treatment with Casodex® (bicalutamide) for locally advanced prostate cancer can detect a difference in the rate of decrease of prostate specific antigen (PSA) levels.
Locally Advanced Prostate Cancer
DRUG: Iressa
Determine the difference in the rate of PSA decrease between treatments over a 6 months period.
To detect changes in prostatic metabolites by using in vivo magnetic resonance spectroscopy (MRS)|To detect changes in prostate gland using magnetic resonance imaging (MRI)|To detect changes in serum tumor markers|To assess histopathological changes
The purpose of this study is to determine if the addition of ZD1839 Iressa™ to standard treatment with Casodex® (bicalutamide) for locally advanced prostate cancer can detect a difference in the rate of decrease of prostate specific antigen (PSA) levels.